Adenovirus Type 6: Subtle Structural Distinctions from Adenovirus Type 5 Result in Essential Differences in Properties and Perspectives for Gene Therapy
Adenovirus vectors are the most frequently used agents for gene therapy, including oncolytic therapy and vaccine development. It’s hard to overestimate the value of adenoviruses during the COVID-19 pandemic as to date four out of four approved viral vector-based SARS-CoV-2 vaccines are developed on...
Main Authors: | Margarita Romanenko, Ivan Osipov, Sergey V. Netesov, Julia Davydova |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-10-01
|
Series: | Pharmaceutics |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4923/13/10/1641 |
Similar Items
-
Development of Oncolytic Vectors Based on Human Adenovirus Type 6 for Cancer Treatment
by: Ivan D. Osipov, et al.
Published: (2023-01-01) -
Oncolytic Adenoviruses in Cancer Treatment
by: Ramon Alemany
Published: (2014-02-01) -
Designer Oncolytic Adenovirus: Coming of Age
by: Alexander T. Baker, et al.
Published: (2018-06-01) -
Development of a low-seroprevalence, αvβ6 integrin-selective virotherapy based on human adenovirus type 10
by: Emily A. Bates, et al.
Published: (2022-06-01) -
Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses
by: Martí Farrera-Sal, et al.
Published: (2020-04-01)